{
  "docId": "019de074-ca9a-70d9-9ba2-1d5f94361fe0",
  "docSlug": "6d754588aa25b32079af055d51113b03",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 38,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a Gantt-style chart to represent clinical trial progress.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ca9a-70d9-9ba2-1d5f94361fe0/4",
  "deckHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0",
  "deckJsonHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0.json",
  "deckAnchorHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.92,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Pipeline development status for Pegtarviliase, Pegzilarginase, and Preclinical Programs",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b93474d4-f990-4403-8bfe-e2b90a38abcf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.92,
        "x": 0.04,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "1~25,000 represents estimated treatment candidates... 4 Market Authorisation Application (MAA) validated by the European Medicines Agency (EMA) and currently under review...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f694b740-63b7-410d-b204-6754fb3ac9b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Aeglea’s Human Enzyme Therapies for Rare Metabolic Diseases",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f0552c3-cda5-45e5-8acd-12a28281cf03",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "923ee479-f887-46c5-8979-f252b2907ebc",
      "evidence": "The slide uses horizontal bars to represent the progress of drug programs across clinical phases.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 38,
      "from": 3,
      "beatId": "e469074b-5500-4414-8b81-ef0652ee8a7d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 3-38 present various traction metrics, including clinical trial results and financial summaries",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}